1. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63(Suppl):1-139.
2. Schatz H, Madeira D, Johnson RN, McDonald HR. Central serous chorioretinopathy occurring in patients 60 years of age and older.
Ophthalmology 1992;99:63-67.
3. Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients.
Doc Ophthalmol 1992;81:379-386.
4. Klein ML, Van Buskirk EM, Friedman E, et al. Experience with nontreatment of central serous choroidopathy.
Arch Ophthalmol 1974;91:247-250.
5. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy.
Br J Ophthalmol 1984;68:815-820.
6. Lu JG, Friberg TR. Idiopathic central serous retinopathy in China: a report of 600 cases (624 eyes) treated by acupuncture.
Ophthalmic Surg 1987;18:608-611.
7. Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser.
Acta Ophthalmol Scand 2001;79:417-421.
8. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids.
Surv Ophthalmol 2002;47:431-448.
9. Lafaut BA, Salati C, Priem H, De Laey JJ. Indocyanine green angiography is of value for the diagnosis of chronic central serous chorioretinopathy in elderly patients.
Graefes Arch Clin Exp Ophthalmol 1998;236:513-521.
10. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy.
Ophthalmology 1984;91:1554-1572.
11. Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography.
Am J Ophthalmol 2000;129:16-20.
12. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy.
Retina 2003;23:1-7.
13. Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy.
Can J Ophthalmol 1989;24:20-23.
14. Spitznas M, Huke J. Number, shape, and topography of leakage points in acute type I central serous retinopathy.
Graefes Arch Clin Exp Ophthalmol 1987;225:437-440.
15. Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit.
Ophthalmologica 1992;205:69-76.
16. Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy.
Br J Ophthalmol 2005;89:562-564.
17. Hirami Y, Tsujikawa A, Sasahara M, et al. Alterations of retinal pigment epithelium in central serous chorioretinopathy.
Clin Experiment Ophthalmol 2007;35:225-230.
18. Piccolino FC, de la Longrais RR, Ravera G, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy.
Am J Ophthalmol 2005;139:87-99.
19. Prunte C. Indocyanine green angiographic findings in central serous chorioretinopathy.
Int Ophthalmol 1995;19:77-82.
20. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy.
Am J Ophthalmol 1996;121:26-34.
21. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy.
Int Ophthalmol 1986;9:37-41.
22. Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.
Retina 2002;22:19-24.
23. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy.
Arch Ophthalmol 1996;114:689-692.
24. Levine R, Brucker AJ, Robinson F, et al. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography.
Ophthalmology 1989;96:854-859.
25. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults.
Ophthalmology 1996;103:2070-2079.
26. Gackle HC, Lang GE, Freissler KA, Lang GK. Central serous chorioretinopathy: clinical, fluorescein angiography and demographic aspects.
Ophthalmologe 1998;95:529-533.
27. Wang M, Sander B, la Cour M, Larsen M. Clinical characteristics of subretinal deposits in central serous chorioretinopathy.
Acta Ophthalmol Scand 2005;83:691-696.
28. Wong R, Chopdar A, Brown M. Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy.
Eye (Lond) 2004;18:262-268.
29. Bujarborua D, Chatterjee S, Choudhury A, et al. Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy.
Retina 2005;25:422-429.
30. Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy.
Am J Ophthalmol 2002;133:787-793.
31. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy.
Acta Ophthalmol 2008;86:126-145.
32. Erickson PA, Fisher SK, Anderson DH, et al. Retinal detachment in the cat: the outer nuclear and outer plexiform layers.
Invest Ophthalmol Vis Sci 1983;24:927-942.
33. Bill A, Tornquist P, Alm A. Permeability of the intraocular blood vessels.
Trans Ophthalmol Soc U K 1980;100:332-336.
34. Anderson DH, Guerin CJ, Erickson PA, et al. Morphological recovery in the reattached retina.
Invest Ophthalmol Vis Sci 1986;27:168-183.
35. Sakai T, Calderone JB, Lewis GP, et al. Cone photoreceptor recovery after experimental detachment and reattachment: an immunocytochemical, morphological, and electrophysiological study.
Invest Ophthalmol Vis Sci 2003;44:416-425.
36. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy.
Am J Ophthalmol 2004;137:1073-1080.
37. Chung SE, Kang JH, Kang SW. Chronic central serous chorioretinopathy: photodynamic therapy. J Korean Ophthalmol Soc 2007;48:279-284.
38. Lai TY, Chan WM, Li H, et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
Br J Ophthalmol 2006;90:869-874.
39. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey.
Ophthalmology 1999;106:1915-1923.
40. Peyman GA, Kazi AA, Unal M, et al. Problems with and pitfalls of photodynamic therapy.
Ophthalmology 2000;107:29-35.
41. Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization.
Invest Ophthalmol Vis Sci 2002;43:2384-2391.
42. Paskowitz DM, Nune G, Yasumura D, et al. BDNF reduces the retinal toxicity of verteporfin photodynamic therapy.
Invest Ophthalmol Vis Sci 2004;45:4190-4196.
43. Cayouette M, Behn D, Sendtner M, et al. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse.
J Neurosci 1998;18:9282-9293.